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Abstract
Thirty-six multidrug-resistant (MDR) Mycobacterium tuberculosis
isolates collected in Japan were examined for pyrazinamide sus-
ceptibility and pyrazinamidase activity, and analysed by pncA
sequencing and a hybridization-based line probe assay (LiPA),
which was used to detect pncA mutations for the rapid identiﬁ-
cation of pyrazinamide-resistant isolates. Pyrazinamide resistance
was found in 19 (53%) of them. All pyrazinamide-resistant iso-
lates had no pyrazinamidase activity and at least one mutation in
pncA. Among the pncA mutations, 11 had not been previously
reported. The results of the LiPA were fully consistent with the
DNA sequencing results. A majority of MDR M. tuberculosis iso-
lates in Japan were resistant to pyrazinamide.
Keywords: Line probe assay, multidrug resistance, Mycobacte-
rium tuberculosis, pncA, pyrazinamide
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The emergence and spread of multidrug-resistant (MDR)
strains of Mycobacterium tuberculosis, which are deﬁned as
strains resistant to both rifampin and isoniazid, constitute a
serious threat to the control of tuberculosis (TB) [1].
Pyrazinamide is a ﬁrst-line anti-TB drug that exhibits
strong activity against semidormant bacilli sequestered within
macrophages, and is used in short-course treatment in com-
bination with rifampin, isoniazid, and ethambutol [2,3]. Pyra-
zinamide is also one of the most important drugs used in the
treatment of MDR TB. It is a prodrug that requires conver-
sion into its active form, pyrazinoic acid, by the bacterial
enzyme pyrazinamidase (PZase), which is encoded by pncA
[4–6]. Mutations in pncA lead to the loss of PZase activity
and constitute the mechanism of pyrazinamide resistance in
M. tuberculosis [5,7,8].
It is essential that rapid drug susceptibility testing (DST)
be developed to prevent the spread of MDR M. tuberculosis.
DST of M. tuberculosis produces reliable results for most
anti-TB drugs [9]. However, conventional DST for pyrazina-
mide is hampered by poor bacterial growth, because pyrazin-
amide requires acidic conditions to be active; therefore, DST
must be performed under such conditions [5]. Liquid cul-
ture-based methods have recently been developed to resolve
this problem [10].
Previously, we described a DNA sequencing-based
method for detecting mutations in the genome of drug-resis-
tant strains, including pyrazinamide-resistant M. tuberculosis
[11]. However, the use of this method in ordinary-scale clini-
cal laboratories can present a problem because of its high
cost. Therefore, we developed a hybridization-based line
probe assay (LiPA) for the rapid detection of pncA mutations
in pyrazinamide-resistant M. tuberculosis that can easily be
used for clinical applications [12].
Thirty-six MDR M. tuberculosis isolates were collected dur-
ing the national surveillance study, from June to November
2002, by the Tuberculosis Research Committee (Ryoken),
Japan [13]. These isolates were obtained from patients with
TB in nine hospitals in Japan located in various regions: one
in Hokkaido, one in Tohoku, four in Kanto, two in Kinki and
one in Kyushu. M. tuberculosis strain H37Rv (ATCC 27294),
which is susceptible to pyrazinamide and positive for PZase,
was used as a positive control for the assay. Mycobacterium
bovis strain BCG (Japanese strain 172), which is resistant to
pyrazinamide and negative for PZase, was used as a negative
control.
Pyrazinamide susceptibility testing was performed with a
broth method (BD BACTEC MGIT 960; BD Biosciences,
Sparks, MD, USA) [9]. PZase activity was determined using
Wayne’s method [14], with some modiﬁcations [12]. Rifam-
pin and isoniazid susceptibility testing were performed with
an egg-based Ogawa medium method. These assays were
performed in one institution (Japan Anti-Tuberculosis Associ-
ation).
Nested PCR was performed to amplify a 670-bp fragment
that includes the entire pncA gene, as described previously
[12]. For DNA sequencing, only the second PCR was
performed. DNA sequences of pncA and its promoter region
(nucleotides )80–572 relative to the initiation codon) were
determined as described previously [11] and compared with
those of H37Rv using GENETYX-MAC (Genetyx Corpora-
tion, Tokyo, Japan).
Forty-seven oligonucleotide probes designed to cover the
entire pncA gene of H37Rv were immobilized on two strips
and used for the LiPA (Table S1). The LiPA was conducted
as described previously [15]. Biotinylated PCR products from
test samples were hybridized to the immobilized probes, and
the strips were washed. The presence or absence of bands
on all strips was judged visually.
Of 36 clinical isolates of MDR M. tuberculosis tested with
the LiPA, 17 were wild type, and the other 19 showed at
least one mutation (Table 1 and Fig. 1). As shown by the
data in Fig. 1, the 17 wild-type isolates (lanes 1–17) and
H37Rv (lane 37) hybridized to all probes. The other 19
isolates did not hybridize to at least one probe
(lanes 18–36). Regarding the pyrazinamide resistance pro-
ﬁle, the LiPA yielded results that were 100% in agreement
with those obtained by culture-based susceptibility testing
(Table 1). All PZase-positive bacilli tested were sensitive to
pyrazinamide, and all PZase-negative bacilli were resistant
to pyrazinamide (Table 1). These data are consistent with
those of previously published reports [11,12]. All of the 19
pyrazinamide-resistant isolates were correctly identiﬁed as
being pyrazinamide-resistant by the LiPA, and all of the 17
pyrazinamide-susceptible isolates were identiﬁed as being
pyrazinamide-susceptible.
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The pncA genes of all isolates tested were sequenced
(Table 1). One or more pncA mutations were identiﬁed in
24 isolates, and 12 isolates had no mutation. Among the
24 isolates with pncA mutations, we found 20 different
mutations, of which 11 have not been previously reported.
Of these 11 novel mutations, four were frameshift
mutations (D59, D(129–130), 261::AC, D(374–389)), ﬁve
were mutations causing an amino acid substitution
(G232A, A340G, G400T, G419A, G493A), one was a non-
sense mutation (C102A), and one was a silent mutation
(C450A) (Table 1). The G419A and G493A mutations are
not associated with pyrazinamide resistance, because the
isolates with these mutations were pyrazinamide-sensitive.
It is unknown whether G232A, A340G and G400T are
associated with pyrazinamide resistance, because isolates
with these mutations had an additional mutation in pncA
that conferred pyrazinamide resistance. As shown in
Table 1, the isolate with the C102A mutation (strain 2P-5-
230) was resistant to pyrazinamide and exhibited no PZase
activity. The C102A mutation changed the 34th amino acid
of PZase into a stop codon, suggesting that the C102A
mutation is associated with pyrazinamide resistance. The
results of the LiPA were fully consistent with the DNA
sequencing results (Table 1). The LiPA correctly identiﬁed
pyrazinamide susceptibility and resistance in all strains in
which a mutation occurred.
We found that 53% of MDR M. tuberculosis isolates (19 of
36) obtained in Japan were resistant to pyrazinamide.
Although the number of MDR isolates detected in this study
was small, the results suggest that the majority of MDR
M. tuberculosis isolates in Japan are resistant to pyrazinamide.
Mphahlele et al. [16] reported that 52% of South African
MDR M. tuberculosis isolates are resistant to PZA. Thus, a
majority of MDR M. tuberculosis isolates in other countries
may also be resistant to pyrazinamide. Clinical trials of the
LiPA for in vitro diagnosis in Japan started in April 2009.
TABLE 1. Identiﬁcation of pncA mutations by line probe assay (LiPA) among 36 multidrug-resistant Mycobacterium tuberculosis
isolates
Strain LiPA proﬁlea Pyrazinamide susceptibility PZase activity
Mutation
Nucleotide change Amino acid change
2A-3-16 Wild type S + – –
2A-3-83 Wild type S + – –
2A-3-84 Wild type S + – –
2A-4-30 Wild type S + – –
2B-7-38 Wild type S + – –
2C-1-46 Wild type S + – –
2G-2-5 Wild type S + – –
2I-11-4 Wild type S + – –
2P-5-113 Wild type S + – –
2P-5-280 Wild type S + – –
2P-5-420 Wild type S + – –
2R-1-48 Wild type S + – –
2C-3-89 Wild type S + G419Ab R140H
2O-2-16 Wild type S + G419Ab R140H
2A-3-142 Wild type S + G419Ab, G493Ab R140H, A165T
2P-5-269 Wild type S + G419Ab, G493Ab R140H, A165T
2C-4-48 Wild type S + G419Ab, C450Ab, G493Ab R140H, G150G, A165T
2A-3-11 D16 R ) T175C S59P
2A-3-14 D7, D20, D21 R ) D59b, G232Ab Frameshift, G78S
2A-3-137 D13, D14 R ) C153A, G493Ab H51Q, A165T
2B-7-33 D15 R ) C161T P54L
2C-3-105 D33 R ) A410C H137P
2E-1-3 D1, D28 R ) T-7C, A340Gb T114A
2E-1-93 D1, D28 R ) T-7C, A340Gb T114A
2O-4-41 D2 R ) C8A A3E
2P-1-57 D12 R ) D(129–130)b, G493Ab Frameshift, A165T
2P-1-114 D23 R ) 261::ACb Frameshift
2P-1-118 D10 R ) T100G Y34D
2P-1-120 D4 R ) T26G V9G
2P-5-58 D2 R ) C8A, G419Ab A3E, R140H
2P-5-108 D23 R ) 261::AC Frameshift
2P-5-167 D10 R ) T100G Y34D
2P-5-230 D10 R ) C102Ab Y34c
2P-5-233 D2 R ) C8A A3E
2P-5-254 D10 R ) T100G, G400Tb Y34D, A134S
2V-5-5 D31, D32 R ) D(374–389)b Frameshift
aD indicates a negative signal at a probe.
bMutation not previously reported.
cOchre mutation.
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Speciation and susceptibility of Nocardia
isolated from ocular infections
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Abstract
Twenty Nocardia spp. isolated from ocular infections were iden-
tiﬁed by 16S rRNA gene sequencing and susceptibility was deter-
mined using the E-test (AB Biodisk, Sweden). Species
distribution among the 20 isolates was as follows: Nocardia levis
(n = 7), Nocardia farcinica (n = 3), Nocardia abscessus (n = 2),
Nocardia brasiliensis (n = 2), Nocardia amamiensis (n = 2), Nocardia
puris (n = 1), Nocardia beijingensis (n = 1), Nocardia otitidiscaviarum
(n = 1) and Nocardia thailandica (n = 1). All isolates were sensi-
tive to amikacin. Eighteen (90%) isolates were sensitive to tobra-
mycin, 11 (55%) to ciproﬂoxacin and gatiﬂoxacin, and seven
(35%) to azithromycin and clarithromycin. Molecular methods
are useful for the identiﬁcation and for the detection of Nocardia
species that have not so far been reported in human infections.
Keywords: N. amamiensis, N. thailandica, N. levis, N. puris, ocular
infections
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